🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to participate in this #RedTalk 😊 Many thanks to Emmanuel Gomez Dr. Guillaume Cartron and Lysa Lymphoma for this opportunity to share our experience treating refractory #lymphoma and #CLL patients with CD19 CAR T cells Fred Hutch Cancer Center

#Vaccination #COVID19 Nous demandons: 👉l’organisation d’un circuit de vaccination des patients ultra- prioritaires au sein des établissements autorisés au traitement du cancer 👉la livraison de doses spécifiquement destinées aux patients Notre lettre à Olivier Véran 👇👇👇

Fabulous! Diffuse Large B-Cell Lymphoma | NEJM nejm.org/doi/full/10.10…

[PUBLICATION] R-GemOx in R/R DLBCL patients not eligible to ASCT retrospective study ✔196 pts, med 72 y, 2nd line: 58% ✔CR: 33% ✔med PFS: 5 mo, OS: 10 mo ✔ In CR patients: PFS: 22 mo 👇 doi.org/10.1080/104281…

Happy 60th birthday to my dear friend and colleague Gilles Salles!

👀 At the #16ICML, Lymphoma Hub spoke with Vincent Camus, CentreHenriBecquerel. We asked, What is the optimal frontline immunochemotherapy for primary mediastinal B-cell lymphoma (PMBL)? Watch it here: 👉 loom.ly/yLikel4 👈 #lymsm #lymphoma

#Nomination | « Par ses valeurs et son histoire, l’Institut Curie porte une profonde dimension humaniste que je m’engage à poursuivre. » A compter du 1er septembre, le Pr Steven Le Gouill 🧑‍⚕️ prend la direction de l’Ensemble Hospitalier de l’Institut Curie. ⬇️

At last together Lysa Lymphoma

Final results of the dose-escalation part of the phase 1-2 study of #Epcoritamab in r/r B-cell #lymphoma now online in #Lancet. We Rigshospitalet are proud and priviliged to be part of this study. #lymsm thelancet.com/journals/lance…

First day stamp from Europe to UK. A giant leap for mankind ?

En 2022, construisons ensemble le futur de la lutte contre le cancer. Le CentreHenriBecquerel vous adresse ses meilleurs vœux pour cette nouvelle année 2022 !

Up to 40% of patients receiving the standard R-CHOP regimen for diffuse large B-cell lymphoma have refractory disease or relapse. A modified regimen might improve outcomes. New research findings are summarized in a short video. nej.md/3rSJ41d

Conclusion, patients do quite well and have limited extra days in hospital despite R-CHOP

Additionally, Also my colleagues from national Cancer Institute (Kiev) did auto SCT for lymphoma patient in a bombshell!!! You cannot plan transplant based on a bombing timetable😡 The EBMT European Hematology Association ASH Stefano Luminari, MD Anna Sureda Mohamad Mohty

Next week, hybrid ELI workshop : “Genomics of lymphoma: from basic to clinical use”

⁦ELI⁩ meeting is just starting in Dubrovnik

The winners of the Bertrand Coiffier 2023 award, Jean Lemoine and Vincent Camus, presented their projects at the LYSA meeting Lysa Lymphoma

Very honored to have received one of the two Bertrand Coiffier 2023 Awards. Thank you very much to ELI , Lysa Lymphoma and the International Jury for awarding this prize allowing me to realize a research mobility in Prof. Davide Rossi's lab at the Institute of Oncology Research (IOR)

Aujourd'hui c'est la journée mondiale du lymphome, mais le(s) connaissez-vous vraiment ?🤔 🎥 En ce #MoisDesCancersDuSang, Dr Lepretre, hématologue au CentreHenriBecquerel, décrypte pour vous le, ou plutôt les, lymphome(s) dans cet épisode de la Minute Hémato👇